Advertisement
News
Advertisement

Consumer Information on: Photodynamic Diagnostic D-Light C (PDD) System - P050027

Mon, 06/14/2010 - 9:38am
U.S. Food & Drug Administration

Diagram of the Photodynamic Diagnostic D-Light C (PDD) System. Indicates PPD Cystoscope, D-Light C, Fluid Light Cable, PDD Camera Head, and Camera Control Unit.This is a brief overview of information related to FDAâ??s approval to market this product. See the links below to the Summary of Safety and Effectiveness Data (SSED) and product labeling for more complete information on this product, its indications for use, and the basis for FDAâ??s approval. 

Product Name: Karl Storz Photodynamic Diagnostic D-Light C (PDD) System

PMA Applicant: Karl Storz Endoscopy-America, Inc.

Address: 2151 E. Grand Avenue, El Segundo, CA 90245

Approval Date: May 28, 2010

Approval Letter: http://www.accessdata.fda.gov/ cdrh_docs/pdf5/P050027a.pdf

What is it? The Karl Storz Photodynamic Diagnostic D-Light C (PDD) System is used as an optional accessory to white light cystoscopy when used in combination with the diagnostic imaging drug Cysview® (Photocure ASA, a Norwegian pharmaceutical company).

The system includes:

  • D-Light-C light Source and Fluid Light Cable
  • PDD Telescopes (cystoscopes)
  • Endovision Telecam® SL and/or Endovision Tricam® SL Camera Control Unit and PDD Camera Head

How does it work? Light is transmitted through a fluid light cable connected to an endoscope to light up the area to be observed. Blue light is used to excite Cysview® that has collected in cancerous tissue.

When is it used? The D-Light C PDD System when used in combination with the Cysview® is used to detect non-muscle invasive papillary cancer of the bladder.

What will it accomplish? Based on evidence collected during a clinical study, Cysview® plus blue light cystoscopy has been demonstrated to detect non-muscle invasive papillary cancer of the bladder.

When should it not be used?

  • Patients with gross hematuria.
  • Patients with porphyria.
  • Patients that have hypersensitivity to Cysview® solution.
  • Patients who have received BCG immunotherapy or chemotherapy with in the last 90 days.
  • Patients who have received a previous dose of Cysview® solution, as the safety and efficacy of repeated use of Cysview® solution has not been established.

Additional information: Summary of Safety and Effectiveness and labeling are available online.

    

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading